메뉴 바로가기
주메뉴 바로가기
컨텐츠 바로가기
Company History
02
Establishment of Huons Meditech (Merger of Huons Medical - Huons Medicare)
12
Acquisition of integrated certification for safety and health management system.
04
Selected as an export voucher business (KOSMES)
03
"Scotelin Plus" product registration completed (China)
12
Selected as Leading Company of Strategic Industry in Busan City (Life Care Sections)
Investement contract for joint development of healthcare robot business (Zeta Bank)
07
ISO 9001 Certification (Seongnam Branch)
Selected as a Busan hidden champion company (Busan City)
Designated as a promising export small and medium business Administration
(Ministry of SMEs and Startups)
05
Designated as a research and development venture company
04
Disinfectant Tissue for human skin "Hexiwipes" approval
ISO 13485 certification (Seongnam Branch)
03
Ophiclean® CE Mark approval
01
Acquired "Medical Device Business Sector" from "WeGreen Inc."
09
Established additional production lines (Disinfectant Tissue)
08
Launching single use collyrium Lybliss 0.15% & Lybliss 0.3%
04
Single use Peracetic Acid (PAA) Disinfectant "Sco-Single" approval
03
Automatic Endoscope Reprocessor (AER) WELL-1 & WELL-2 approval
02
Peracetic Acid (PAA) Disinfectant "Scotelin® Plus" approval
10
Medical device manufacturing industry approval
08
Acquired "Medical Device Business Sector" from "M Technology Inc."
04
Changed name to Huons medicare Co., Ltd.
05
Huons Group changed into a holding company system
01
First disinfectant exportation to Japan (Company "KRD JAPAN")
09
Signed export contract to China on Scotelin® (Company "Carewin")
06
Changed Representative Director & CEO (Mr. Lee Sang Man)
03
Changed Representative Director & CEO (Mr. Jeon Gyu Seop)
10
Patent application for Peracetic Acid (PAA) dialysis solution composition without acetic acid ion.
08
Emofen-C Tab. L-car Inj. approval
06
Ridifen eye drops, Ritobra eye drops, Rioflox eye drops, Riflu eye drops, Riflu-T eye drops, Ritobra eye drops approval
04
Changed name to Huniz Co., Ltd.
01
Rebliss eye drops (Sodium hyaluronate), Hexi-al solution 2% (Chlorhexidine gluconate) approval
12
Ritanol eye drops (Olopatadine hedrochloride) approval
09
Huniz Fluconazole Cap approval
06
Acquiring item (Elprin Tab)
07
Changed Representative Director & CEO (Mr. Lee Sang Deuk)
12
Awarded with excellent firm for KFDA self-audit
07
Acquisition of quality certification for sanitary product and GH mark (Hemoclean®, Scotelin®)
10
Patent application of manufacturing method for Peracetic Acid solution with new technology
07
Hold the first "Int's Hemoclean Conference"
12
Awarded $ one million export
11
Written in casebook about success of support of the policy
01
Designated as leading company of top 10 business strategy
06
KFDA for Korea's first PAA - "Hemoclean®, Hemoclean® RP" approval
09
Designated as an excellent small-medium enterprise and enterpriser
08
Awarded with 2005 Venture enterpriser
10
Affliated laboratory received citation for "Man of Merit in Science and Technology Promotion" (The Minister of Science and Technology)
04
"Hemoclean®" received world's first FDA approval on "PAA based disinfectant for artificial kidney"
11
Selected "Top 100 Excellent Patents in Technology 2003" (Korean Intellectual Property Office (KIPO), The Hankook Ilbo (韓國日報))
02
Awarded "Korea's Exellent Venture Company" (Seoul Economy Newspaper)
01
Changed Representative Director & CEO (Mr. Lee Jin Tae)
12
Won the grand prize in "Digital Innovation Awards 2002" (Minister of Commerce, Industry and Energy Award)
08
ISO 9001, 13485, SGS UK, "Hemoclean®" CE Mark
04
Completion of Clean Room (KGMP, CE, cGMP standards)
01
Signed 3 million USD export contract on "Hemoclean®" (Gambro K.K., Japan)
05
Received official approval on "Affiliated Medical Chemistry Laboratory" (Korea Industrial Technology Association (KOITA))
04
Patent application for Peracetic Acid (PAA) production method
01
Started marketing "HEMOCLEAN®"
10
Establishment
03
First developed Peracetic Acid (PAA) for medical device cleaner & disinfectant in Korea